Tazemetostat in Malignant Peripheral Nerve Sheath Tumors
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This phase 2, open label, single arm study will investigate the use of tazemetostat in
patients with recurrent/refractory and/or metastatic malignant peripheral nerve sheath
tumors.